Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)

Funding Agency:
National Institutes of Health

This funding opportunity announcement (FOA) invites applications to establish a Resource Center (RC) for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (Consortium) that has the ultimate goal to design new immunotherapy and combination interventions in PDAC.

The RC will support the administrative coordination of the Consortium, create and support database(s) for data pertinent to the Consortium. It will secure centralized tissue banking for specimens submitted by the members of the Consortium and a virtual biospecimen database that would include all tissue resources of the Consortium. The RC will provide centralized bioinformatics and data analysis support, establish in vivo and in vitro model repositories and distribution units. Lastly, the RC will support meeting and communications coordination among members of Consortium, and form and maintain a Consortium website.

The companion FOA of the PDAC Consortium includes:

RFA-CA-17-015, "Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)"

Deadlines:

  • Letter of Intent Due Date(s): February 7, 2017
  • Application Due Date(s): March 7, 2017

RFA-CA-17-016​ Expiration Date March 8, 2017

Agency Website

Eligibility Requirements

The PD/PIs of the RC should have understanding of and research experience with PDAC in general. Administrative leadership experience is necessary. Additional expertise in bioinformatics, and animal models, is expected from the PD/PI or from peers in a multiple PD/PI collaboration.

Amount

$1,750,000

Amount Description

Direct costs are limited to $350,000 per year.

The total project period request may not exceed 5 years.

Funding Type

Grant

Eligibility

Faculty

Category

Interdisciplinary
Medical
Medical - Basic Science
Medical - Translational

External Deadline

March 7, 2017